Evidence Hub

Evaluating the Efficacy of Thymus vulgaris L. from the Garmian Region: Chemical Composition and Clinical Application for Gastric Bacterial Infections

Yaser Khorram Del, Mahir Essa Alsalihi, Darya Shorsh Hamad, Azadeh Khorram Del, Dlshad Namiq Khurshed, Mohammed N. Saeed

Galla Journal, 2025

48 participants

Abstract

Thymus vulgaris L. (thyme) is being studied as a potential adjunct therapy for Helicobacter pylori (H. pylori) infections. H. pylori is a Gram-negative bacterium associated with peptic ulcers and gastric cancer. Alternative treatment options are needed due to declining efficacy of conventional antibiotics. Bioactive compounds in thyme, such as p-cymene, carvacrol, and thymol, exhibit strong antimicrobial activity and have been widely used in traditional medicine. A three-week clinical trial involving 48 patients with infections compared thyme extract to a standard triple therapy (Pylokit: tinidazole, clarithromycin, and lansoprazole). The thyme extract significantly reduced bacterial load, with an average drop of 5.14 units by week three. This demonstrates greater efficacy than the chemical treatment and showed no adverse effects. Chemical tests with GC-MS showed thymol (59.99%) as the predominant antimicrobial constituent, followed by carvacrol and p-cymene. These findings suggest that thyme may represent a safe, natural, and effective therapeutic option against H. pylori, warranting further large-scale clinical investigations.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free